Day 2 of the SDPA Summer Conference ended with an illuminating lecture on eyelid malignancies by Dr. Michael Yen, an oculoplastic surgeon. The most common eyelid malignancy is basal cell cancer representing 95% of eyelid malignancies. Suspicious characteristics for eyelid malignancies include growth, lid notching, ulceration, telangiectasias and deepening pigmentation. Madarosis, or loss of eyelashes, …
Dr. John Wright, an oral pathologist, presented an illuminating lecture on orocutaneous disease at the SDPA Annual Summer Conference. Dr. Wright began his talk with viral presentations of disease focusing on herpes simplex virus (HSV). Herpes simplex is a systemic virus which presents as a vesiculobullous disease. With primary herpes outbreak, it often presents panorally …
The second product theater on day 2 of the SDPA Annual Summer Conference presented by Robert Casquejo, PA-C discussed Otezla as a treatment for adult patients with active psoriatic arthritis and patients with moderate to severe plaque psoriasis who are candidates for phototherapy and systemic therapy. Otezla is an oral medication that inhibits phosphodiesterase 4 …
The first product theater on day 2 of the SDPA Annual Summer Conference was presented by Dr. Neal Bhatia and featured the use of Onexton and Retin-A Micro for the treatment of acne. Acne vulgaris is an inflammatory pilosebaceous disease that affects greater than 80% adolescents, up to 12% women, and can persist after the …
Day 2 of the SDPA Annual Summer Conference started with an enlightening lecture on nephrocutaneous disease presented by Dr. Jennie Clarke. For reasons that are not completely understood, xerosis and pruritis are the two most common presentations of patients with end stage renal disease. Unfortunately, dialysis does not help improve these conditions. Treatment of these …
Andrea Nguyen, MS, PA-C presented the second product theater on the first day of the SDPA Annual Summer Conference. She discussed Cosentyx, the first and only fully human Il-17A antagonist approved for the treatment of psoriatic arthritis and moderate to severe plaque psoriasis. Cosentyx is also indicated for the treatment of ankylosing spondylitis. Ms. Nguyen …